Use of c-Src inhibitors alone or in combination with STI571 for the treatment of leukaemia

Use of c-Src inhibitors alone or in combination with STI571 for the treatment of leukaemia

  • CN 1,523,991 A
  • Filed: 08/09/2002
  • Published: 08/25/2004
  • Est. Priority Date: 08/10/2001
  • Status: Active Application
First Claim
Patent Images

1. combination;

  • it comprises the chemical compound of a) at least a c-Src of reduction protein tyrosine kinase activity and (b) N-{5-[4-(4-methyl-Piperazino-methyl)-benzoyl-amido]-the 2-aminomethyl phenyl }-4-(3-pyridine radicals)-2-pyrimidine-amine and randomly at least a pharmaceutically useful carrier;

    active component wherein all exists with the form of free form or officinal salt in all cases, and described combination is used for simultaneously, uses respectively or successively.

View all claims
    ×
    ×

    Thank you for your feedback

    ×
    ×